Saturday 17 October 2026 Export MESO’s income statement to Excel — free account

Mesoblast Limited

Mesoblast Limited’s revenue for fiscal 2026 (year ended June 2026) was $120.3 million, up 599.2% from fiscal 2025. Insiders bought in the last twelve months.

13.28 0.67 −4.80%

Follow MESO

Alert me

Market cap: $1.8B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 5/9
Altman Z: 3.40
Beneish M: 2.37
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 37.53

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	2	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1,810.00

Revenue 7.50

Net Income (128.61)

Free Cash Flow (84.36)

Net Debt (3.10)

Current Ratio 1.58

Debt/Equity 0.22

P/E ratio 0.00

Fwd P/E —

P/S ratio 137.69

P/B ratio 1.80

Past 5Y EPS Growth —

This Y EPS Growth 57.36%

Next Y EPS Growth 179.40%

Next Y revenue growth —

Next 5Y EPS Growth 48.80%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 79.12%

10-year low 10-year high

P/B against its own 10 years 73.98%

10-year low 10-year high

EV/Sales against its own 10 years 80.74%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	71	63	162	103
Receivables	7	21	15	58
Inventory	—	—	22	28
Other	—	—	—	—
	82	86	204	197

	2023	2024	2025	2026
Payables	20	7	19	47
ST’ Debt	6	14	54	11
Other	12	50	27	21
	42	73	103	81

Compound Annual Growth %

	10y	5y	3y
Sales	10.95%	74.39%	152.15%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.74%	(0.45%)	4.24%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	—	—	—	—	120
’25	—	—	—	—	17
’24	—	—	—	—	6
’23	2	2	2	2	8
’22	4	2	2	2	10
’21	1	2	2	2	7

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	—	(30)	—	—	(44)
’25	—	(21)	—	—	(50)
’24	—	—	—	—	(48)
’23	(14)	(16)	(16)	(16)	(63)
’22	(18)	(18)	(15)	(14)	(66)
’21	(28)	(29)	(24)	(19)	(101)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	—	(31)	—	—	(45)
’25	—	(21)	—	—	(51)
’24	—	0	—	—	(49)
’23	(14)	(16)	(16)	(16)	(64)
’22	(18)	(18)	(16)	(14)	(66)
’21	(28)	(30)	(25)	(19)	(102)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	—	—	—	—	(0.44)
’25	—	—	—	—	(0.85)
’24	—	—	—	—	(0.89)
’23	(0.24)	(0.34)	(0.26)	(0.28)	(1.10)
’22	(0.34)	(0.40)	(0.32)	(0.34)	(1.40)
’21	(0.42)	(0.44)	(0.44)	(0.34)	(1.64)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	9.60	6.70	8.28	6.24	7.82	4.28	1.94	1.61	9.61	12.94	Analyst estimates 2027–2029 Powerpack
	High	25.00	17.56	15.18	42.56	27.40	10.18	10.24	22.00	21.88	21.50
People
People	Employees	75	81	83	102	83	77	83	73	81	108
	Revenue/emp, $m	0.03	0.21	0.20	0.32	0.09	0.13	0.09	0.08	0.21	1.11
Income, $m
Income, $m	Revenue	2	17	17	32	7	10	8	6	17	120
	Gross margin, %	(400.21)	68.24	8.16	21.29	(338.83)	(166.48)	(269.72)	100.00	70.17	86.14
	EBT	(90)	(66)	(99)	(87)	(100)	(92)	(82)	(88)	(102)	(57)
	EBT margin, %	(3,740.26)	(380.47)	(590.56)	(271.66)	(1,336.24)	(896.93)	(1,094.53)	(1,493.51)	(592.00)	(47.31)
	Net income	(77)	(35)	(90)	(78)	(99)	(91)	(82)	(88)	(102)	(57)
	Depreciation	3	3	2	4	4	4	4	5	6	9
Per share, $
Per share, $	Revenue	0.06	0.37	0.34	0.61	0.12	0.16	0.10	0.06	0.14	0.93
	Earnings	(1.94)	(0.76)	(1.82)	(1.48)	(1.64)	(1.40)	(1.10)	(0.89)	(0.85)	(0.44)
	Cash flow	(2.39)	(1.61)	(1.17)	(1.07)	(1.67)	(1.01)	(0.81)	(0.49)	(0.41)	(0.34)
	Capex	(0.01)	0.00	(0.01)	(0.04)	(0.03)	0.00	0.00	0.00	(0.01)	(0.01)
	Free cash flow	(2.40)	(1.62)	(1.17)	(1.11)	(1.69)	(1.02)	(0.82)	(0.49)	(0.42)	(0.35)
	Book value	12.95	11.72	9.73	10.39	9.61	7.66	6.45	4.87	4.95	4.39
	Shares, m	40	47	49	53	61	65	78	99	121	129
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	263.05	32.49	29.86	37.46	121.40	28.22	81.08	70.30	112.91	140.28
	P/B	1.23	1.03	1.04	2.19	1.56	0.58	1.21	1.04	1.84	1.83
	EV/Sales	244.08	33.74	31.71	36.22	115.68	31.76	86.07	75.39	123.70	139.87
	EV/FCF	(6.13)	(7.76)	(9.10)	(19.87)	(8.41)	(4.91)	(10.15)	(7.45)	(13.25)	(12.44)
Cash, $m
Cash, $m	Operating cash flow	(95)	(75)	(58)	(56)	(101)	(66)	(63)	(48)	(50)	(44)
	Capex	0	0	0	(2)	(2)	0	0	0	(1)	(1)
	Free cash flow	(96)	(75)	(58)	(59)	(102)	(66)	(64)	(49)	(51)	(45)
Balance, $m
Balance, $m	Working capital	27	77	18	46	54	18	40	13	102	116
	Total debt	—	59	81	89	94	97	109	114	122	119
	Net debt	(46)	22	31	(40)	(43)	36	37	51	(40)	16
	Shareholders’ equity	517	546	481	549	581	497	502	480	597	568
Returns, %
Returns, %	ROA	(11.47)	(5.24)	(13.36)	(11.25)	(13.37)	(12.99)	(12.30)	(13.14)	(14.05)	(7.38)
	ROIC	(11.97)	(7.06)	(10.67)	(8.99)	(10.31)	(8.71)	(7.18)	(7.66)	(8.83)	(3.53)
	ROE	(14.70)	(6.64)	(17.49)	(15.13)	(17.48)	(16.94)	(16.40)	(17.91)	(18.95)	(9.86)

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2023

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SRPT Sarepta Therapeutics, Inc.	$1.9B	— (loss-making)	4.4×	−34.34% (below 0%: shrinking)	n/m	−14.48% (below 0%: shrinking)	62.77%	3.31%	Compare
MRVI Maravai LifeSciences Holdings, Inc.	$1.8B	— (loss-making)	— (loss-making)	+8.53% (above 0%: growing)	n/m	+127.57% (above 0%: growing)	40.14%	(29.33%)	Compare
ZYME Zymeworks Inc.	$1.8B	— (loss-making)	16.2×	−90.58% (below 0%: shrinking)	n/m	−385.53% (below 0%: shrinking)	(497.71%)	(918.95%)	Compare
PVLA Palvella Therapeutics, Inc.	$1.8B	— (loss-making)	— (loss-making)	−99.09% (below 0%: shrinking)	n/m	−136.38% (below 0%: shrinking)	100.00%	0.00%	Compare
MESO Mesoblast Limited	$1.8B	— (loss-making)	—	−13.41% (below 0%: shrinking)	n/m	−89.23% (below 0%: shrinking)	(353.35%)	(909.40%)
URGN Urogen Pharma	$1.8B	— (loss-making)	— (loss-making)	+199.22% (above 0%: growing)	n/m	+17.26% (above 0%: growing)	90.93%	0.15%	Compare
XNCR Xencor, Inc.	$1.8B	— (loss-making)	— (loss-making)	+17.46% (above 0%: growing)	n/m	−52.91% (below 0%: shrinking)	100.00%	(72.37%)	Compare
VIR Vir Biotechnology, Inc.	$1.8B	— (loss-making)	— (loss-making)	+19,582.54% (above 0%: growing)	n/m	+200.47% (above 0%: growing)	100.00%	30.75%	Compare
SEPN Septerna, Inc.	$1.8B	— (loss-making)	— (loss-making)	+22,375.63% (above 0%: growing)	n/m	−9.01% (below 0%: shrinking)	100.00%	(62.95%)	Compare
Median of peers	$1.8B	—	—	+13.00%	—	−11.74%	95.47%	(14.66%)

All 614 Biotechnology stocks →

Mesoblast Limited (MESO) key facts

Concern: Mesoblast Limited reported a net loss of $57.5 million, or a loss of $0.44 per share, for fiscal 2026.
Strength: Mesoblast Limited’s revenue for fiscal 2026 (year ended June 2026) was $120.3 million, up 599.2% from fiscal 2025.
Mesoblast Limited (MESO) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, MESO traded at $13.28, a market capitalization of $1.8 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 138× sales.
Return on equity was −9.86% and debt-to-equity 0.22.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 3.40 (safe zone) for fiscal 2026.